|Bid||16.27 x 1100|
|Ask||16.28 x 1100|
|Day's range||16.14 - 16.74|
|52-week range||2.35 - 23.34|
|Beta (3Y monthly)||-0.13|
|PE ratio (TTM)||N/A|
|Earnings date||4 May 2017 - 8 May 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||34.80|
New clinical data gave investors pause, while management wisely took advantage of the soaring stock price to raise capital through a share offering.
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Amarin Corporation plc (AMRN) today announced the pricing of the underwritten public offering of its American Depositary Shares ("ADSs") for gross proceeds of approximately $200.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Amarin. In addition, Amarin has granted the underwriters a 30-day option to purchase approximately $30.0 million of additional ADSs. Jefferies and Cantor Fitzgerald & Co. are acting as the joint book-running managers for the offering.
Amarin Corporation plc (AMRN) today announced a registered underwritten public offering of its American Depositary Shares (“ADSs”). All of the shares in the proposed offering are to be sold by Amarin. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. Jefferies and Cantor Fitzgerald & Co. are acting as the joint book-running managers for the offering.
Amarin stock rose from $2.35 at the close of market on December 29, 2017, to $18.97 at the close of market on November 21, 2018, reflecting a ~449% year-to-date rise. Amarin hit its 52-week high of $23.34 on November 6. Amarin’s net revenue in the first nine months of 2018 amounted to $151.9 million compared to $127.2 million in the same period of the previous year, reflecting a ~19% YoY (year-over-year) rise.
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 20, 2018 -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of.
Amarin Corporation plc’s (NASDAQ:AMRN): Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company’s Read More...
In the first nine months of 2018, Amarin reported revenues of $151.3 million, which is 20.0% YoY growth. Analysts expect Amarin to report a gross margin of 75.43% in 2018, which will be a rise of 25 basis points YoY. The company is expected to witness a gross margin of 76.67% in 2019, which will be an improvement by 123 basis points YoY.
Currently, Amarin (AMRN) is focused on creating awareness for Vascepa across new territories. According to Amarin’s third-quarter earnings conference call, the company is initially targeting territories that have the potential to become profitable in a short timeframe. Amarin has been targeting ~20,000 general practitioners to increase Vascepa’s adoption. General practitioners are the first physicians that patients visit when they’re suffering from high cardiovascular risk. General practitioners account for almost 85% of the total physicians that Amarin is targeting. Among the remaining physicians, ~7% are cardiologists and 5% are endocrinologists.
According to Amarin’s (AMRN) third-quarter earnings conference call, the company secured prescription approval rates of 75% for Vascepa from Managed Care organizations—similar to the approval rates witnessed by generic Lovaza. The company has been witnessing rapid revenue growth for Vascepa, despite a narrow label and low salesforce. Amarin is focused on capacity expansion, which could support more than $1.0 billion worth of Vascepa’s net revenues in 2019.
In the third-quarter earnings conference call, Amarin (AMRN) didn’t provide any revenue guidance for the fourth quarter, 2018, or 2019. After the REDUCE-IT trial results, Amarin aims to increase the number of sales representatives in the US market to 400 by the beginning of 2019. According to Amarin’s third-quarter earnings conference call, the expanded sales force and primary results published in the American Heart Association presentation on November 10 are expected to drive Vascepa’s revenue growth in future quarters.
On November 12, Amarin (AMRN) stock closed at $19.82, which is 5.84% lower than its previous closing price. On November 10, Amarin issued a press release announcing favorable primary results from the cardiovascular outcomes trial—REDUCE-IT. Despite the favorable outcomes from REDUCE-IT, the stock has been impacted negatively due to queries raised by researchers and cardiologists about the use of mineral oil as a placebo in the cardiovascular outcomes trial.
Amarin (AMRN) posts detailed data from a late-stage cardiovascular outcomes study on its fish oil drug Vascepa. The stock takes a hit.